Markets

Taking a Look at the Operational Data for Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 12.94B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Nektar Therapeutics (NASDAQ:NKTR) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NKTR, the company currently has 37.97 million of cash on the books, which is offset by 2.48 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 582.06 million in total assets, balanced by 497.89 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Nektar Therapeutics (NKTR) saw 92.14 million in free cash flow last quarter, representing a quarterly net change in cash of 21.82 million. Perhaps most importantly where cash movements are concerned, the company saw about 93.08 million in net operating cash flow.



Nektar Therapeutics (NASDAQ:NKTR) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 152.93 million in total revenues. That represents a quarterly year/year change in revenues of 3.21 in sequential terms, the NKTR saw sales decline by 3.42.

But what about the bottom line? After all, that’s what really matters in the end. Nektar Therapeutics (NKTR) is intriguing when broken down to its core data. The cost of selling goods last quarter was 5.67 million, yielding a gross basic income of 147.25 million. For shareholders, given the total diluted outstanding shares of 162.64 million, this means overall earnings per share of 0.37. Note, this compares with a consensus analyst forecast of -0.35 in earnings per share for its next fiscal quarterly report.




Is Nektar Therapeutics (NASDAQ:NKTR) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.27 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Nektar Therapeutics.

Previous ArticleNext Article

Related Post

AstraZeneca PLC (AZN): Are There Still Some Opport... It's worth it to have a look at AstraZeneca PLC (NYSE:AZN) as there may be a chasm between the bulls and the bears as far as recent trading activity g...
Does Pure Storage, Inc. (PSTG) Present Much Upside... Pure Storage, Inc. (NYSE:PSTG) is an interesting stock at present. Now trading with a market value of 3.55B, the company has a mix of catalysts and ob...
Does Acacia Research Corporation (ACTG) Present Mu... Acacia Research Corporation (NASDAQ:ACTG) is in the highlights and many would want to know whether now might be a good time for it to present much ups...
Does Symantec Corporation (SYMC) Present Much Upsi... It's worth it to have a look at Symantec Corporation (NASDAQ:SYMC) as there may be a chasm between the bulls and the bears as far as recent trading ac...
Anthera Pharmaceuticals, Inc. (ANTH) Forming A Pat... Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is in the highlights and many would want to know whether now might be a good time for it to present much u...